Request Demo
Last update 31 Jul 2025
DuoCAR20.19.22-D95(University of Kansas Medical Center)
Last update 31 Jul 2025
Overview
Basic Info
Drug Type CAR-T |
Synonyms Duo-CAR-T cells targeting cell surface antigens CD19/20/22((University of Kansas Medical Center)) |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD20 modulators(B-lymphocyte antigen CD20 modulators), CD22 modulators(CD22 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with DuoCAR20.19.22-D95(University of Kansas Medical Center)NCT06879340
A Phase 1 Multicenter, Open Label Trial Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
100 Clinical Results associated with DuoCAR20.19.22-D95(University of Kansas Medical Center)
Login to view more data
100 Translational Medicine associated with DuoCAR20.19.22-D95(University of Kansas Medical Center)
Login to view more data
100 Patents (Medical) associated with DuoCAR20.19.22-D95(University of Kansas Medical Center)
Login to view more data
100 Deals associated with DuoCAR20.19.22-D95(University of Kansas Medical Center)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | United States | 31 Mar 2025 | |
| B-Cell Malignant Neoplasm | Phase 1 | United States | 31 Mar 2025 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | United States | 31 Mar 2025 | |
| High grade B-cell lymphoma | Phase 1 | United States | 31 Mar 2025 | |
| Marginal Zone B-Cell Lymphoma | Phase 1 | United States | 31 Mar 2025 | |
| Mediastinal large B-cell lymphoma | Phase 1 | United States | 31 Mar 2025 | |
| Pre B-cell acute lymphoblastic leukemia | Phase 1 | United States | 31 Mar 2025 | |
| T-cell/histiocyte rich large B-cell lymphoma | Phase 1 | United States | 31 Mar 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free